Showing results (2361-2370 of 2,751) with videos related to
Sort By:
Pageof 276
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.Neurology. Genetics|December 7, 2022
Somatic Variants in SVIL in Cerebral AneurysmsPui Man Rosalind Lai, Jee-Yeon Ryu, Sang-Cheol Park, et al.Journal of Medical Genetics|December 20, 2011
A novel microdeletion syndrome at 3q13.31 characterised by developmental delay, postnatal overgrowth, hypoplastic male genitals, and characteristic facial featuresAnna-Maja Molin, J Andrieux, D A Koolen, et al.Blood|September 28, 2007
The EUROclass trial: defining subgroups in common variable immunodeficiencyClaudia Wehr, Teemu Kivioja, Christian Schmitt, et al.Blood|November 5, 2008
Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromesUlrich Salzer, Chiara Bacchelli, Sylvie Buckridge, et al.Plos One|August 14, 2015
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidRonald C Hendrickson, Anita Y H Lee, Qinghua Song, et al.Frontiers in Radiology|February 2, 2024
High resolution and contrast 7 tesla MR brain imaging of the neonatePhilippa Bridgen, Raphael Tomi-Tricot, Alena Uus, et al.The Lancet. Neurology|October 19, 2016
Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trialDaniel F Hanley, Richard E Thompson, John Muschelli, et al.Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.Circulation. Cardiovascular Genetics|September 17, 2015
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyPaul N Hopkins, Joep Defesche, Sigrid W Fouchier, et al.Pageof 276